LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)

Launched by UNIVERSITY OF ALBERTA · Jun 4, 2024

Keywords

ClinConnect Summary

The WISDOM trial is studying the effectiveness of a lower dose of continuous renal replacement therapy (CRRT) compared to the standard dose in critically ill patients with acute kidney injury. CRRT is a type of dialysis used to help patients whose kidneys are not working well. The goal of this study is to see if the lower dose is just as safe and effective as the standard dose, while also being potentially less expensive.

To participate in this trial, you must be at least 18 years old, weigh 55 kg or more, and be starting CRRT or have started it within the past 24 hours. You should also be expected to survive and receive CRRT for at least 48 hours. If you join the study, you will receive either the standard dose or the lower dose of CRRT, and your health outcomes will be monitored. It’s important to know that some patients may not qualify for the trial if they need a higher dose of CRRT or have other specific kidney conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age ≥ 18 years
• • weight ≥ 55 kg
• • plan to initiate CRRT or within 24 hours of having started CRRT for AKI
• • expected to survive and receive CRRT for a duration of ≥ 48 hours
• • able to provide informed consent or have an authorized representative provide consent after being informed on the details and risks of the trial unless a deferred consent process is approved by local Research Ethics Board (REB).
• Exclusion Criteria:
• • indication for sustained higher dose-intensity CRRT as designated by the attending clinicians
• • end-stage kidney disease receiving maintenance dialysis
• • receipt of any RRT for AKI during the current hospitalization
• • inability to comply with the requirements of the study protocol.